PMID- 38193374
OWN - NLM
STAT- MEDLINE
DCOM- 20240308
LR  - 20240308
IS  - 1531-703X (Electronic)
IS  - 1040-8746 (Linking)
VI  - 36
IP  - 2
DP  - 2024 Mar 1
TI  - Unveiling the role of cellular dormancy in cancer progression and recurrence.
PG  - 74-81
LID - 10.1097/CCO.0000000000001013 [doi]
AB  - PURPOSE OF REVIEW: Cellular dormancy is a major contributor to cancer progression 
      and recurrence. This review explores recent findings on the molecular mechanisms 
      implicated in cancer dormancy and investigates potential strategies to improve 
      therapeutic interventions. RECENT FINDINGS: Research on cancer dormancy reveals a 
      complex and multifaceted phenomenon. Providing a latent reservoir of tumor cells 
      with reduced proliferation and enhanced drug-tolerance, dormant cancer cells 
      emerge from a clonally diverse population after therapy or at metastatic sites. 
      These cells exhibit distinct transcriptional and epigenetic profiles, involving 
      the downregulation of Myc and mechanistic target of rapamycin (mTOR) pathways, 
      and the induction of autophagy. Senescence traits, under the control of factors 
      such as p53, also contribute significantly. The tumor microenvironment can either 
      promote or prevent dormancy establishment, notably through the involvement of T 
      and NK cells within the dormant tumor niche. Strategies to combat 
      dormancy-related relapse include direct elimination of dormant tumor cells, 
      sustaining dormancy to prolong survival, or awakening dormant cells to 
      re-sensitize them to antiproliferative drugs. SUMMARY: Improving our 
      understanding of cancer dormancy at primary and secondary sites provides valuable 
      insights into patient care and relapse prevention.
CI  - Copyright (c) 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Collignon, Evelyne
AU  - Collignon E
AD  - Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Centre 
      (U-CRC) and Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, 
      Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240102
PL  - United States
TA  - Curr Opin Oncol
JT  - Current opinion in oncology
JID - 9007265
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Humans
MH  - *Neoplasms/metabolism
MH  - *Antineoplastic Agents
MH  - Tumor Microenvironment
EDAT- 2024/01/09 06:41
MHDA- 2024/03/08 06:43
CRDT- 2024/01/09 05:43
PHST- 2024/03/08 06:43 [medline]
PHST- 2024/01/09 06:41 [pubmed]
PHST- 2024/01/09 05:43 [entrez]
AID - 00001622-990000000-00140 [pii]
AID - 10.1097/CCO.0000000000001013 [doi]
PST - ppublish
SO  - Curr Opin Oncol. 2024 Mar 1;36(2):74-81. doi: 10.1097/CCO.0000000000001013. Epub 
      2024 Jan 2.